Title: Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers.

Authors:


Affiliations:

1Department of Head and Neck Surgery, 2Department of Bioinformatics and Computational Biology, 3Department of Radiation Oncology, 4Department of Pathology, 5Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 6Human Genome Sequencing Center, 7Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas;

Running Title: Genomic analysis of young tongue cancer.

Keywords: Young tongue cancer, SCCOT, Head and neck/oral cancers, Tobacco

Abbreviations: squamous cell carcinoma of the oral tongue (SCCOT), head and neck squamous cell carcinoma (HNSCC), young tongue (YT), old tongue (OT), MD Anderson Cancer Center
(MDA), TCGA HNSCC project (HNSC), copy number alterations (CNA), lung adenocarcinoma (LUAD), bladder urothelial carcinoma (BLCA)

Notes: word count 3498, 2 figures and 2 tables

Financial support: This work was supported by the Cancer Prevention Research Institute of Texas grant RP100233; National Institutes of Health (NIH)/National Institute of Dental and Craniofacial Research grant RC2DE020958; NIH Specialized Program of Research Excellence grants P50CA097007; Cancer Center Support Grant P30CA16672 and the Pantheon Program.

Corresponding author: Jeffrey N Myers, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1445, Houston TX 77030. Phone: 713-745-2667; Fax: 713-794-4662; Email: jmyers@mdanderson.org

Conflicts: The authors disclose no potential conflicts of interest.
Statement of Translational Relevance: Genomic alterations do not explain the increasing incidence of oral tongue cancer in young patients, and smoking does not dramatically alter the genome of tongue cancer at any age. Therefore, the causes of tongue cancer are still largely unknown, and their identification could provide novel avenues for therapeutic intervention.

Abstract:

Purpose: Epidemiological studies have identified an increasing incidence of squamous cell carcinoma of the oral tongue (SCCOT) in younger patients.

Experimental Design: DNA isolated from tongue tumors of young (<45 yrs, non-smokers) and old (>45 yrs) patients at was subjected to whole-exome sequencing and copy number analysis. These data were compared to data from similar patients in the The Cancer Genome Atlas (TCGA) project.

Results: In this study, we found that gene-specific mutation and copy number alteration frequencies were similar between young and old SCCOT patients in two independent cohorts. Likewise, the types of base changes observed in the young cohort were similar to those in the old cohort even though they differed in smoking history. TCGA data also demonstrate that the genomic effects of smoking are tumor-site specific, and we find that smoking has only a minor impact on the types of mutations observed in SCCOT.

Conclusions: Overall, tumors from young SCCOT patients appear genomically similar to those of older SCCOT patients, and the cause for the increasing incidence of young SCCOT remains unknown. These data indicate that the functional impact of smoking on carcinogenesis in SCCOT is still poorly understood.
Introduction: Epidemiological studies have recently identified increasing incidence of squamous cell carcinoma of the oral tongue (SCCOT) in younger patients(1-3). These tumors are not HPV-related and are often found in women who are non-smokers(2, 4). Those observations contrast with most SCCOT cases which are seen in older men with a history of cigarette smoking(5). The causes for this increasing incidence in the young are unknown. We hypothesized that this epidemiologically distinct disease would also prove to be genomically distinct, especially with respect to alterations caused by smoking, and that a better understanding of the differences would identify novel opportunities for treatment and/or prevention. Hence, we undertook the sequencing and integrated genomic profiling of a cohort of younger SCCOT patients, as reported here.

Patients and Methods: Fresh-frozen surgically resected previously untreated tumor tissue and matched nonmalignant adjacent tissue were obtained from consented patients treated for head and neck squamous cell carcinoma (HNSCC) at The University of Texas MD Anderson Cancer Center (Houston, TX), under an Institutional Review Board-approved protocol. Young tongue patients were chosen based on oral tongue primary tumor site, age less than 46 and less than 1 pack-year smoking history. Old tongue patients were chosen based on oral tongue primary tumor site and age greater than 45. Patient characteristics are shown in Table S1. Exome DNA was captured with Nimblegen reagents (Nimblegen) and sequenced on a SOLiD or Illumina platform as described previously(6). SNP analysis was conducted on SNP6.0 or CytoscanHD arrays (Affymetrix), and the data were analyzed with Partek (v6.6, Partek Inc.), ASCAT (v2.1), GISTIC (v2.0.12), and R software, as described previously(6). We have previously reported sequencing and copy number data from some of these patients(6, 7). Mutation data can be found in Supplemental Table S3.
A similar cohort of patients was identified from within the TCGA HNSCC project. YT patients were chosen based on oral tongue site, age less than 46 and lifelong non-smoker or reformed smoker with unknown pack-year history. OT were chosen based on oral tongue site and age greater than 45. Patient characteristics are shown in Table S1. Mutation and copy number data were obtained from the TCGA pan-cancer project(8) and the Synapse website(9) (www.synapse.org, doi:10.7303/syn300013).

The statistical significance of mutation and copy number frequencies was determined by Fisher’s exact test. Mutation type frequencies were determined for each patient, excluding indels and multiple-base mutations. Group frequencies were determined by averaging the individual patient frequencies: this prevented skewing of the data by patients with large numbers of mutations. Mutation type frequencies were compared by using the t-test on arcsine transformed data.

**Results:** DNA from 16 young tongue (YT) and 28 old tongue (OT) patients treated at MD Anderson Cancer Center (MDA) was subjected to whole-exome sequencing (Table S1). A median of 29 and 83 mutations were identified in the YT and OT tumors, respectively. The elevated number of mutations in the OT is not surprising, since mutation number is known to be related to both age and smoking (10). This finding was validated in The Cancer Genome Atlas (TCGA) cohort, in which the median number of mutations increased from 63 in YT to 112 in OT. Figure S1 shows the relationships between mutation number and age. We next asked whether any specific genes were mutated at a different frequency in the YT cohort. Because of the low sample size we limited our initial search to the most significantly mutated genes identified by MutSig in the entire TCGA HNSCC project (HNSC). *TP53* (unadjusted p=0.015) showed a slight increase in mutation frequency in the MDA YT cohort, but it was not statistically significant when adjusted for multiple testing (Table 1, Fig 1). Comparable analysis
was then performed on the TCGA cohort. The TP53 mutation frequency was also elevated in the TCGA YT patients (Table 1, Fig 1). In order to increase statistical power the two cohorts were combined. Three genes showed trends toward statistical significance; FAT1, TP53, and PIK3CA (Table 1, Fig 1). However, none of those genes showed a statistically significant difference between the combined YT and OT patient cohorts. The trend of increased TP53 mutations in YT is provocative since the YT lack exposure to cigarette smoke, which has been associated with TP53 mutations. FAT1 and PIK3CA showed a lower mutation frequency in the YT cohort. Mutation frequencies for HPV-positive tumors and the entire TCGA cohort are shown for comparison (Table 1). An analysis of mutation frequencies in all genes in the combined cohorts was also performed, but no genes were found to be significantly different. Additional subset analysis for really young tongues (<30yo), OT smokers, and OT non-smokers are shown in Table S2.

Whole genome copy number analysis was also performed. We compared the number and size of copy number alterations (CNA) between the YT and OT cohorts, identifying an average of 129 CNAs in YT samples and 72 in the OT samples from the MDA cohort (Table 2), and 62 and 64 CNAs in the YT and OT samples from the TCGA cohort, respectively (Table 2). These differences were not statistically significant, although the YT had a smaller mean segment length for copy number gains (p=0.00817) (Table 2) in the MDA cohort. There was no difference in segment length of losses in between YT and OT in either cohort (Table 2). The mean copy number of gains or losses was also not different for gains or losses in either cohort (Table 2). Finally, no specific genomic regions were found to be significantly different between the YT and OT patients in either the MDA cohort or the TCGA cohort. Analysis of some genes frequently gained or lost in HNSCC revealed modest differences in frequency between YT and OT (Fig 1).
For example, gains in *FADD* and *PIK3CA* were less frequent in YT, but the difference was not significant (Fig 1). Overall, the CNAs were very similar between the YT and OT cohorts, and the regions of copy number change were similar to those reported previously(6).

Since smoking is known to leave its mark on the genome by causing certain types of mutations, we compared mutation types in the YT and OT patients. Taking into account directional redundancy, six types of mutations can be distinguished. The frequencies of these 6 types of mutations have been shown to vary across tumor types(8, 11), but we found no significant difference in that respect for YT and OT patients in either the MDA or TCGA cohort (Fig 2A). The profiles resembled that of all head and neck tumors in the TCGA project. The profile, however, was distinct from that of HPV+ tumors or laryngeal tumors (Fig 2A). HPV+ tumors show an increase in C>T mutations (p<0.0001) and decreases in C>A, A>T (both p<0.0001) and A>G (p=0.0074) mutations when compared with HPV- HNSC tumors. Laryngeal tumors show a decrease in C>T mutations (p<0.0001) and increases in C>A and A>T mutations (both p<0.0001) when compared with non-laryngeal tumors (Fig 2A). It was expected that OT tumors would exhibit a mutation signature related to cigarette smoking when compared with the YT tumors from non-smokers. The similarity between YT and OT mutation signatures could indicate either the presence of a smoking signature in the YT tumors or a lack of a smoking signature in the OT tumors. To address those alternative possibilities, we investigated the smoking signatures in other tumor sites from the TCGA project.

The mutational events linked to smoking are traditionally reported as an increase in C>A mutations and a decrease in C>T mutations. TCGA collected smoking history information for lung adenocarcinoma (LUAD), bladder urothelial carcinoma (BLCA), and HNSC. Each of these tumor types was analyzed for the presence of a smoking mutation signature. In LUAD tumors
C>A mutations increased 23.7 percentage points in smokers when compared to non-smokers, and C>T mutation decreased 18.7 percentage points (Fig 2B, C). A>T mutations were also found to increase 2.9 percentage points in smokers (Fig 2B, C).

BLCA showed a very different profile, indicating the effect of tissue of origin. BLCA show a much higher frequency of C>T and C>G mutations and a lower frequency of C>A when compared with LUAD (Fig 2B). In BLCA the impact of smoking is quite different from that in LUAD. The largest change with smoking in BLCA is a decrease in C>G of 6.6 percentage points (Fig 2B, C). C>A is also increased 4.5 percentage points, but neither change is statistically significant (Fig 2B, C).

We next examined the impact of smoking on the mutation profile of HNSC. The changes in HNSC were generally similar to those in LUAD but of lower magnitude. We found a decrease in C>T of 13.2 percentage points and an increase in C>A of 7.3 percentage points that were consistent with the changes in LUAD (Fig 2B, C). HNSC also demonstrated increases in A>G and A>T of 3.8 and 3.1 percentage points, respectively (Fig 2B, C, S2A).

Having defined the smoking signature, we could then ask whether YT and OT tumors exhibit such a signature. For this analysis we combined the YT and OT tumors into one cohort (YT/OT) and compared it with the HNSC smoking and non-smoking cohorts. The YT/OT cohort had a lower C>A frequency and a higher C>T frequency when compared with the HNSC smoking cohort (Fig 2C), indicating that the YT/OT tumors lack the most definitive characteristics of the smoking signature. However, the YT/OT also demonstrated increased A>G when compared with the HNSC non-smoking tumors and an intermediate level of A>T when compared to both smoking and non-smoking cohorts (Fig 2C). Similar results were obtained when the YT and OT
cohorts were separately compared to the non-smoking and smoking cohorts, although with lower statistical significance (data not shown) or when smoking and non-smoking cohorts within the OT cohort were compared to each other or YT (Fig S2B). Overall, the mutation profile of the YT/OT tumors appears most similar to the profile of non-smokers.

Since both YT and OT tumors lack a smoking signature we next searched for the source of the smoking signature in HNSC. We found that tumors from the laryngeal subsite exhibit a smoking signature when compared with tumors from all other sites (Fig 2A, C, S2A, B) with an increase in C>A mutations and a decrease in C>T mutations. Additionally, the smoking signature within the oral tongue subsite is less recognizable than the overall HNSC smoking signature (Fig 2C). Those observations suggest that the smoking signature in HNSC is largely driven by the laryngeal subsite.

**Discussion:** Since the incidence of YT cancer has reportedly been increasing(1-3) we hypothesized that YT and OT tumors would prove to be genomically distinct. We found, to the contrary, that the two are genomically quite similar in their copy number alterations, mutations and types of mutations. Those conclusions were consistent for two independent patient cohorts. Although this study is the largest genomic analysis of YT tumors it is still limited by the small sample size. The rarity of these tumors has also prevented ideal matching of the YT and OT cohorts, which differ in a few parameters (Table S1), and resulted in a YT cohort that is not enriched for women as some have reported(2, 4).

The mutation frequencies of FAT1 and TP53 showed trends toward statistical significance, but would require larger cohorts for validation (estimated 170 and 189 total patients, respectively). FAT1 is inactivated in a large proportion of oral cavity tumors, either by mutation or copy
number deletion(6). FAT1 may be related to differentiation, migration or Hippo signaling in HNSCC(6, 12-14), but its role is largely still unknown. The lower frequency of FAT1 mutations in YT could suggest that its inactivation is not necessary for tumor formation or that it is somehow related to smoking status. However, since older smokers are expected to have more background mutations it is possible that the difference is an artifact of the increased frequency of mutations. Since TP53 mutations are more frequent in YT patients this result is not likely to be an artifact. TP53 mutations are likely to be impactful on the tumor progression in YT, but a causative factor leading to increased TP53 mutations in YT is still unknown.

We also noted that OT tumors do not exhibit a mutation signature associated with smoking. The mutation signature from smoking appears to be site-specific, with laryngeal SCC exhibiting the strongest smoking signature among the HNSCC subsites. SCCOT did not exhibit a robust mutational smoking signature, in that regard echoing the TCGA findings in urothelial bladder cancer(15). Overall, the mutational signature that has been defined by analysis of lung tumors does not appear to reflect the effect of smoking on other tissue sites. Since smoking is clearly an epidemiological risk factor for SCCOT(5) the mechanism of carcinogenesis may differ among sites. Cigarette smoke has been shown to be both a tumor initiator and a tumor promoter(16, 17). Only the role of smoke as a tumor initiator should leave a mutational signature on the DNA. Therefore, it is clear that smoke is a tumor initiator in lung cancer and laryngeal SCC. However, it may act primarily as a tumor promoter in SCCOT and BLCA. It is also possible that epigenetic alterations are involved since we have not yet examined the DNA methylation status of these tumors.

Alcohol consumption is a known risk factor for HNSCC. In some patients alcohol is likely to contribute as an initiator. Ethanol is not mutagenic, but its metabolite, acetaldehyde, can lead to
mutations, primarily C>T(18). Since C>T is the most common mutation in many tumor types(8, 11) other factors must also contribute to their frequency. Analysis of the TCGA HNSC data for an alcohol mutation signature resulted in a less dramatic version of the smoking signature with decreases in C>T and increases in C>A in heavy drinkers (data not shown). That observation contrasts with the expected increase in C>T that could be caused by acetaldehyde. Since many heavy drinkers are also heavy smokers it is likely that the smoking signature masks any alcohol signature. Therefore, the impact of alcohol use is still unclear.

These findings do not lessen the importance of smoking and drinking cessation programs to reduce SCCOT incidence. However, they suggest possible new avenues for prevention or treatment of SCCOT. If an unknown tumor initiator is acting in SCCOT, its identification could lead to new prevention strategies. Our analysis of the mutation profile does not indicate an obvious tumor initiator for SCCOT. It may, however, eliminate some candidates (e.g. many environmental mutagens) that would be expected to leave a mutation signature. It is also possible that the same initiator is acting in both YT and OT patients.

If smoking is indeed a tumor promoter in SCCOT, it will be important to determine the mechanism. In lung cancer, smoke has been shown to function as a tumor promoter by increasing inflammation(16), and that might also be the case in SCCOT. Inflammation from other causes promotes many tumor types including; esophageal, pancreatic, and colorectal(19). That connection suggests that inflammation is an important factor in non-smoking related SCCOT, as previously reported(20, 21). Prevention strategies that include anti-inflammatory agents may prove useful. Although the results of clinical trials of COX inhibitors for prevention of SCCOT have not generally been positive(20, 22), agents that target other inflammatory pathways (such as the NFκ-B pathway) still look very promising(20).
Another factor that could be promoting SCCOT is the oral microbiome. The oral cavity is home to a diverse population of microorganisms (23, 24), even in healthy individuals, and some of those microorganisms could also play a role in carcinogenesis (21, 25). They may produce carcinogenic compounds such as acetaldehyde, inducing local inflammation, or they may act through still-undiscovered mechanisms (21, 24, 25). Numerous microorganisms have already been associated with the development of oral cancer (21, 24, 25). Included are species of *Streptococcus*, *Neisseria*, and *Candida*. Conversely, the “normal” microbiome may protect against carcinogenesis and a disrupted microbiome may cause it to no longer be protective (23, 24). Finally, it is unlikely that microorganisms are directly oncogenic in the way that HPV is oncogenic in oropharyngeal cancer. HPV is the only virus detected in SCCOT, and it is found in only 5% of cases. Additionally, we found that HPV leaves a distinct mutation signature and expect that other pathogens would also leave distinct mutation signatures. However, we detect no such signature. In sum, the oral microbiome is likely to be involved in SCCOT in some way, but very little is understood about its causal role or the specific organisms involved.

Finally, YT cancer is troubling in that it defies the stereotype of HNSCC, which generally occurs in older men with long histories of heavy smoking and drinking (5). That observation is even more disturbing because the incidence of YT cancer is increasing (1-3). Hence, there is a strong interest in identifying the cause. Clinically, the cancer-specific outcomes for YT patients are similar to those for OT patients (4, 26-29), and we have shown here that the genomic alterations in YT tumors are also similar to those in OT tumors. Therefore, the only evidence suggesting that they are a unique cohort is epidemiological (1-3). Although statistically significant, the epidemiological findings are based on a low number of patients, since YT tumors are still quite rare, and the apparent difference could be a statistical anomaly. Additional epidemiological
studies will be necessary to validate the original reports. Our data indicate that the mechanistic
cause of YT cancer is likely to be similar to the mechanistic cause of OT cancer. For example, if
smoking causes inflammation to promote OT perhaps another factor that also induces
inflammation is promoting YT, resulting in a genomically and clinically similar disease.
Similarly a factor that disrupts the oral microbiome in YT could promote carcinogenesis in a way
similar to the mechanism in OT. However, the identity of a causative factor in YT cancer, if it
exists, is still unknown.

Acknowledgements: We thank our patients for their courage and generosity. We thank the
members of the Myers lab for moral support, technical support, and helpful discussions. This
work was supported by the Cancer Prevention Research Institute of Texas grant RP100233 (to
J.N. Myers); National Institutes of Health (NIH)/National Institute of Dental and Craniofacial
Research grant RC2DE020958 (to J.N. Myers); NIH Specialized Program of Research
Excellence grants P50CA097007; Cancer Center Support Grant P30CA16672; an Institutional
Research Grant from the University of Texas M.D. Anderson Cancer Center (to M.J. Frederick)
and the Pantheon Program.

Figure Legends:

Figure 1: Frequency of common genomic alterations in YT and OT. The frequency of each
event in the MDA cohort is shown by a bar to the left of center and the frequency in the TCGA
cohort is shown by a bar to the right of center.

Figure 2: Analysis of mutation profiles. A) The frequency of each type of single base
substitution is indicated by a different color in each annotated HNSC cohort. B) Frequency
distributions by smoking status and tissue site. C) Differences in frequency between 2 cohorts.
The sample name indicates which samples were compared. For example S-NS indicates that the frequency in the NS cohort was subtracted from the frequency in the S cohort, therefore a positive result is a higher frequency in the S cohort. * p<0.0001, # p<0.001, ^ p<0.01.


References:


<table>
<thead>
<tr>
<th>Cohort (N)</th>
<th>MDA</th>
<th>TCGA</th>
<th>Total</th>
<th>unadjusted p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YT (16)</td>
<td>OT (28)</td>
<td>YT (13)</td>
<td>OT (58)</td>
</tr>
<tr>
<td>Median # mutations (range)</td>
<td>28.5 (10-81)</td>
<td>83 (11-251)</td>
<td>63 (9-136)</td>
<td>112 (11-268)</td>
</tr>
<tr>
<td>FAT1</td>
<td>6.3%</td>
<td>25.0%</td>
<td>7.7%</td>
<td>25.9%</td>
</tr>
<tr>
<td>TP53</td>
<td>93.8%</td>
<td>57.1%</td>
<td>92.3%</td>
<td>84.5%</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>0.0%</td>
<td>10.7%</td>
<td>7.7%</td>
<td>17.2%</td>
</tr>
<tr>
<td>CDKN2A</td>
<td>6.3%</td>
<td>3.6%</td>
<td>30.8%</td>
<td>32.8%</td>
</tr>
<tr>
<td>CASP8</td>
<td>6.3%</td>
<td>10.7%</td>
<td>7.7%</td>
<td>6.9%</td>
</tr>
<tr>
<td>AJUBA</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>5.2%</td>
</tr>
<tr>
<td>NOTCH1</td>
<td>25.0%</td>
<td>17.9%</td>
<td>7.7%</td>
<td>22.4%</td>
</tr>
<tr>
<td>MLL2</td>
<td>0.0%</td>
<td>7.1%</td>
<td>7.7%</td>
<td>8.6%</td>
</tr>
<tr>
<td>NSD1</td>
<td>0.0%</td>
<td>3.6%</td>
<td>0.0%</td>
<td>6.9%</td>
</tr>
<tr>
<td>HLA-A</td>
<td>0.0%</td>
<td>14.3%</td>
<td>0.0%</td>
<td>1.7%</td>
</tr>
<tr>
<td>TGFBR2</td>
<td>0.0%</td>
<td>0.0%</td>
<td>0.0%</td>
<td>1.7%</td>
</tr>
</tbody>
</table>
Figure 1

Frequency of alterations

<table>
<thead>
<tr>
<th>Alteration</th>
<th>MDA</th>
<th>TCGA</th>
</tr>
</thead>
<tbody>
<tr>
<td>FAT1 mut</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53 mut</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIK3CA mut</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FADD/CCND1 gain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDKN2A loss</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSMD1 loss</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIK3CA gain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGFR gain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FAT1 loss</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Downloaded from clincancerres.aacrjournals.org on April 8, 2017.
### Table 2

**Copy number alterations**

<table>
<thead>
<tr>
<th></th>
<th>MDA</th>
<th>TCGA</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>YT</td>
<td>OT</td>
<td>p-value</td>
</tr>
<tr>
<td>Mean number all CNAs</td>
<td>129.00</td>
<td>71.56</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>57.94</td>
<td>36.52</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>71.06</td>
<td>35.04</td>
<td>NS</td>
</tr>
<tr>
<td>Mean copy number a,b</td>
<td>3.45</td>
<td>3.09</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>-1.14</td>
<td>-1.41</td>
<td>NS</td>
</tr>
<tr>
<td>Mean segment length (Mb)</td>
<td>7.37</td>
<td>20.50</td>
<td>0.00817</td>
</tr>
<tr>
<td></td>
<td>11.39</td>
<td>15.24</td>
<td>NS</td>
</tr>
</tbody>
</table>

a) MDA values are normalized absolute copy numbers,
b) TCGA values are log2 centered at 0.
Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers

Curtis R Pickering, Jiexin Zhang, David M Neskey, et al.

Clin Cancer Res  Published OnlineFirst May 29, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-14-0565

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2014/07/16/1078-0432.CCR-14-0565.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.